Studies have shown that LGALS1 is significantly overexpressed in the tumor microenvironment of DLBCL, and its high expression is closely related to resistance to CD20 monoclonal antibody therapy (26). This evidence concerns the gene LGALS1 and diffuse large B-cell lymphoma.